Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, critically review the clinical trial data supporting the use of PARP inhibitors and bevacizumab as first-line maintenance therapy in ovarian cancer.